Drug intelligence / Profile preview

SD II

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Inhalation

Overview

SD II is a spray-dried inhalation formulation of BIBN 4096 BS, also known as olcegepant. BIBN 4096 BS is a potent and selective small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. It was developed by Boehringer Ingelheim for the acute treatment of migraine. Studies have shown that BIBN 4096 BS effectively blocks the effects of CGRP, a neuropeptide implicated in migraine pathogenesis, by antagonizing CGRP receptors. This formulation was investigated for its safety, tolerability, and pharmacokinetics in healthy volunteers via inhalation.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on SD II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD II.

Explore the full profile